DrugDevCovid19

Tracking the relevant researches of CADD drug development against COVID-19

Enoxacin

ID MW HBD HBA
3229  320.324
RB NOA Rings logP
473-0.20

Function

DrugBank ID:

DB00467


Description:

A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. [DrugBank]

Targets:

DNA gyrase subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)); DNA topoisomerase 4 subunit A (Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)); DNA topoisomerase 2-alpha (Humans) [DrugBank]

Pharmacodynamics:

Enoxacin is a quinolone/fluoroquinolone antibiotic. Enoxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Enoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Enoxacin may be active against pathogens resistant to drugs that act by different mechanisms. [DrugBank]

Structures

SMILES:

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21

2D structures:  

3D structures:  

Docking in target protein

Receptor: Mpro

Docking Site: Catalytic pocket

Ligand: Enoxacin

Vina score: -7.3

Off-target analysis based on ligand similarity (Homo sapiens)

Step 1 - Target prediction for Enoxacin: SwissTargetPrediction

Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Enoxacin in the SMILES input box.

Step 2 - Blind docking for Enoxacin: CB-Dock

Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Enoxacin to perform blind docking.